InQpharm Group
29
0
0
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
10.3%
3 terminated/withdrawn out of 29 trials
89.7%
+3.1% vs industry average
52%
15 trials in Phase 3/4
19%
5 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
Role: lead
Benefit and Tolerability of IQP-LU-104 in Weight Loss
Role: lead
Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea
Role: lead
Efficacy and Safety of Litramine in 1 Year Weight Loss Study
Role: lead
Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness
Role: lead
Vasoactive Effects of IQP-AS-118 in Healthy Individuals
Role: lead
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
Role: lead
Benefit of IQP-AO-101 for Sleep
Role: lead
Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity
Role: lead
Benefit and Tolerability of IQP-AE-103 in Weight Loss
Role: lead
Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others
Role: lead
Efficacy and Safety of IQP-AK-102 in Reducing Appetite
Role: lead
Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects
Role: lead
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
Role: lead
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
Role: lead
Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects
Role: lead
Efficacy and Safety of IQP-VV-102 in Weight Management
Role: lead
Litramine for Weight Loss
Role: lead
Litramine in Weight Maintenance
Role: lead
Efficacy and Safety of Zenoctil in Reducing Body Weight
Role: lead